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edu.sa (MAbstract Montelukast is a highly selective leukotriene-receptor antagonist (LTRA). It is widely
used in the treatment of bronchial asthma, primarily as an adjunct to corticosteroids. Reactive oxy-
gen species (ROSs) play an important role in the pathogenesis of asthma and oxidative stress con-
tributing to the initiation and worsening of inﬂammatory respiratory disorders, such as asthma.
Antioxidant drugs may have a role in minimizing or preventing damage in asthmatic children.
The aim of this study was to assess the antioxidant effect of montelukast on the production of free
radicals in the whole blood and polymorphonuclear neutrophils (PMNs) in asthmatic children. A
group of 48 (38 males and 10 females), apparently healthy asthmatic children were recruited with
ages ranging between 6 and 14 years. In asthmatic children, base line (premedication) and post med-
ication free radicals activity in the whole blood and polymorphonuclear neutrophils (PMNs) wasy. Production and hosting by
Saud University.
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216 M.M. Al Saadi et al.determined by measuring chemiluminescence (CL) response through chemiluminescence lumino-
meter. Free radical productions were signiﬁcantly decreased in the whole blood, when stimulated
with Phorbol Myristate Acetate (p< 0.04) and Opsonised Zymosan (p< 0.05). The free radicals
were also signiﬁcantly decreased in isolated polymorphonuclear neutrophils (PMNs) when stimu-
lated with Opsonised Zymosan (p< 0.05) after the post medication treatment of montelukast in
asthmatic children. Montelukast decreased the reactive oxygen species production, both in the
whole blood as well as isolated PMNs in asthmatic children.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Montelukast is highly selective antagonist of cysteinyl leuko-
triene (CysLT) receptors. It is commonly used in the treat-
ment of bronchial asthma (Anonymous, 2004; Currie et al.,
2005; Diamant and van der Molen, 2005; Riccioni et al.,
2007; Al-Saadi, 2007). It has both anti-inﬂammatory as well
as bronchodilator effects (Bousquet et al., 2009). Montelukast
is an attractive drug, because it is available in an oral prepa-
ration form, which is easy to administer in children; and
once-daily dosing is practically suitable to achieve greater
compliance. It has a wide therapeutic window with low tox-
icity at therapeutic concentrations, appears safe and well tol-
erated by the patients (Cantrell and Farson-Collier, 2004).
Montelukast has been found to reduce the symptoms of
cough and wheeze, following bronchiolitis in infancy and
has become popular in the treatment of bronchial asthma
(Bisgaard et al., 2003).
The therapeutic effect of montelukast is achieved through
antagonism of CysLT-mediated bronchoconstriction, in-
creased vascular permeability and mucus secretion, following
release of these mediators, mainly from monocytes/macro-
phages, eosinophils, mast cells and basophils. It also acts
through the anti-inﬂammatory actions targeting type 2 helper
CD4+ T-lymphocytes (Peters-Golden and Henderson, 2007).
Unlike corticosteroids, montelukast has been reported to mod-
ulate airway remodelling in patients with chronic asthma (Muz
et al., 2006; Henderson et al. 2006).
Bronchial asthma is the most common chronic inﬂamma-
tory disease of childhood and its prevalence has substantially
increased worldwide, particularly in pre-school children. It is
associated with signiﬁcant morbidity and economic burden
(Harmanci, 2007). In bronchial asthma, mast cells, eosino-
phils and lymphocytes are involved in the expression of an
inﬂammatory process in response to triggering agents in sus-
ceptible individuals. It is well-known that oxygen-derived
free radicals contribute to the inﬂammation in asthma.
When PMNs are stimulated in vivo, their phoslipase is acti-
vated and leukotrienes are liberated through the lipoxyge-
nase pathway. The leukotrienes contribute to oxidative
stress and the initiation and worsening of asthma. They
actually produce typical presentation of the late phase of
an asthma attack. The pharmacological indications of Mont-
elukast have been well established, but its clinical signiﬁ-
cance is still lacking in certain areas, such as its role in
free radicals production. Therefore, the aim of the present
study was to investigate the possible antioxidant effect of
montelukast in asthmatic children, using in vitro chemilumi-
nescence technique in the whole blood and isolated ploymor-
phonuclear neutrophils.2. Subjects and methods
The present study was conducted in the Departments of Pedi-
atrics and Physiology, College of Medicine, King Saud Univer-
sity, Riyadh, Saudi Arabia from the year 2006–2008. The
Ethics Committee, College of Medicine Research Centre
(CMRC) approved the study.
2.1. Subjects
In this study, a group of 48 apparently healthy, volunteers,
asthmatic children (38 males and 10 females) with ages ranging
between 6 and 14 years, were recruited from the various hospi-
tals in Riyadh. The mean duration of the disease was
4.55 ± 0.44 years. The participating children or their parents
completed a questionnaire, which included anthropometric
data and a consent form.
2.2. Exclusion criteria
Children with gross anemia, known history of diabetes melli-
tus, autoimmune diseases and malignancy were excluded. Chil-
dren with current or previous history of cigarette smoking
were also excluded from the study.
2.3. Methods
Blood (5–6 ml) was collected from each child by venipuncture
in a disposable syringe. Blood was heparinized (10 IU/ml
Fischer Scientiﬁc Co., NJ) and the tubes containing this hepar-
anized blood were immediately kept in ice, to prevent any reac-
tions to the time of measurement of free radicals activity by
measuring the chemiluminescence (CL) response. Each speci-
men bottle was labeled with the subject identiﬁcation code
number.
2.4. Chemiluminescence assay
LKB-Wallac 125l Luminometer is a bench top, microcomputer
controlled luminescence-measuring instrument capable of pro-
viding instantaneous monitoring of reactive oxygen species
events. This Luminometer is attached to a display unit and
printer. Disposable polystyrene cuvettes suitable for the Lumi-
nometer and micropipettes with disposable tips for dispensing
100–1000 l1 volumes were used.
2.5. Reagents: preparation of luminol
Liminol (LKB-Wallac 1234–216) was dissolved in dimethyl
sulfoxide (DMSO) to give a concentration of 1.77 mg/ml. It
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17.7 lg/ml prior to use .
2.6. Preparation of phorbol myristate acetate (PMA solution)
PMA was dissolved in DMSO to give a stock solution of 2 mg/
ml. The solution was stored at 20 C until used. It was further
diluted with phosphate buttered saline (PBS) to 20 lg/ml, prior
to use.2.7. Phosphate-buffered saline solution (PBS)
It was made up in distilled water according to the follow-
ing composition NaCl 0.14 M, KCL 2.7 mM, Na2HPO2
mM, KH2PO4 1.5 mM, CaCl2 0.9 mM, and MgCl2
0.49 mM.2.8. Polymorphonuclear neutrophils (PMN) separation
PMNs were separated by using Neutrophils isolation medium
(NIM) obtained from Cardinal Associates Inc, Santa Fe, NM
87502. In a 15 ml tube, 5–6 ml of heparinized blood was lay-
ered over 4 ml of NIM and then centrifuged at 400g for
30 min, at room temperature. After centrifugation, the blood
was separated into layers according to the weight of the cells.
Carefully, the leukocyte-rich plasma (appears as pinkish ring)
was removed with a Pasteur pipette and transferred to a
15 ml conical centrifuge tube. The tube was ﬁlled with PBS
and centrifuged at 350g for 10 min in a Heraeus (Model
GmbH, Osterode). The residual erythrocytes were lysed in
2 ml of lysing buffer (E-lyse) obtained from Cardinal Associ-
ate Inc. Santa Fe, NM 87502, which was vortexed to resus-
pend the pellets and then centrifuged at 250g for 10 min.
The supernatant was discarded and the sediment was sus-
pended in 1 Ml of 5% FCS. The cells were counted and ad-
justed to 5 million/ml.Table 1 Effects of Montelukast on free radical production in
the whole blood (WB), stimulated with PMA and OPZ in
asthmatic children.
Parameters Asthmatic children
premedication
Asthmatic children
post medication
p-Value2.9. Isolated PMNS assay
The cuvette contents were mixed gently and conveyed to the
measurement position. The light emission was recorded in
mV. The assay temperature was kept constant at 37.0 C. Each
sample was measured over a period of 30 min; the results were
plotted using a computer in a graph with Y-axis representing
the light intensity in mV and X-axis representing the time in
minutes.(n= 48) (n= 48)
PMA(CL-mV)
Median 14.40 10.15 0.04
Range 47.30 31.69
Interquartile range 14.20 13.15
OPZ(CL-mV)
Median 24 21.75 0.05
Range 100.60 213.80
Interquartile range 39.92 22.25
CL = Chemiluminescence response, PMNs = Polymorphonuclear
Neutrophils; OPZ = Opsonised Zymosan; PMA= Phorbol Myr-
istate acetate. PMN concentration = 5 · 106 cells/ml; OPZ con-
centration = 1.25 mg/ml; Luminol concentration = 104 M.
Values are expressed as median, range, and interquartile range.2.10. Antileukotriene (Montelukast) in vitro-study
Montelukast was purchased from Sigma Chemical Company,
St. Louis MO, USA and the drug was supplied as a pure
and authentic powder. To each 2 mg of the 6 ll of 1 N, sodium
hydroxide was added until the mixture appeared pasty. The
100 ll of polyethylene glycol (400 MWT) were added. This
paste-like material was warmed at low temperature, until a
clear solution was obtained. This was made up to the required
volume of 2 ml by adding PBS (pH 7.4). The PBS was added in
increasing amount, to avoid precipitation of the compound.
This stock solution was further diluted to the required concen-
tration (range 1.25–60 lg/ml).2.11. Effects of different concentrations on ROS generation from
PMNS
The effect of Montelukast on the generation of ROS, as as-
sessed by CL was determined by addition of different concen-
trations of the drug to isolated PMNs that were stimulated
with PMA.
2.12. Effect of incubation time on ROS generation
The effect of Montelukast (5 and 10 lg) on ROS generation
was tested at different time intervals: 0, 10, 30, and 60 min
after incubation at 37 C.
2.13. Reversibility of the effect of Montelukast
In order to investigate whether Montelukast would have a per-
manent effect on PMNs or not, two different concentrations of
30 and 60 lg were incubated for 45 min with isolated PMNs
and washed thereafter several times with PBS. The CL of un-
washed and washed samples in the presence of Montelukast
was recorded.
2.14. Statistical analysis
The data were analyzed by using a SPSS Pc+ version 16.0 Sta-
tistical program. The descriptive statistics, median, range and
inter quartile range values were used to describe the outcome
variables, due to the skewed distribution of outcome variables.
The comparison of pre and post values of outcome variables
was carried out by applying a non parametric Wilcoxon Signed
Ranks Test. A p-value of <0.05 was considered as statistically
signiﬁcant.
3. Results
In this study on asthmatic children, base line (premedication)
and post medication free radicals activity in the whole blood
and polymorphonuclear neutrophils (PMNs) was determined
Table 2 Effects of Montelukast on free radical production in
isolated polymorphonuclear neutrophils PMNs, stimulated
with PMA and OPZ in asthmatic children.
Parameters Asthmatic
children
premedication
(n= 48)
Asthmatic
children
post
medication
(n= 48)
p-Value
PMA (CL-mV)
Median 398.55 245.35 0.08
Range 1494 1363
Interquartile range 280.80 244.30
OPZ (CL-mV)
Median 1517.45 1171 0.04
Range 3551.70 4002.60
Interquartile range 1144.37 1913.20
CL = Chemiluminescence response, PMNs= Polymorphonuclear
Neutrophils; OPZ = Opsonised Zymosan; PMA= Phorbol Myr-
istate acetate. PMN concentration = 5 · 106 cells/ml; OPZ con-
centration = 1.25 mg/ml; Luminol concentration = 104 M.
Values are expressed as median, range, and interquartile range.
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chemiluminescence luminometer.
Table 1 shows the effects of Montelukast on free radical
production in the whole blood, (WB) stimulated with phorbol
myristate acetate (PMA) and opsonised zymosan (OPZ) in
asthmatic children. The median, range, and Interquartile range
values were obtained from the whole blood in asthmatic chil-
dren. There was a signiﬁcant decline in free radical production
in the whole blood (WB) stimulated with phorbol myristate
acetate (PMA) (p< 0.04) and opsonised zymosan (OPZ)
(p< 0.05) in asthmatic children before and after the treatment
with montelukast.
Table 2 demonstrates the effects of montelukast on free
radical production in isolated Polymorphonuclear neutrophils
(PMNs), stimulated with phorbol myristate acetate (PMA)
and opsonised zymosan (OPZ) in asthmatic children. The med-
ian, range, and interquartile range values were measured be-
fore and after the medication of montelukast. There was a
signiﬁcant decrease in free radical productions in isolated
PMNs when stimulated with OPZ (p< 0.043) in asthmatic
children. However, no signiﬁcant difference was achieved
when stimulated with PMA (p= 0.08).4. Discussion
Montelukast is a selective and orally active leukotriene recep-
tor antagonist, that inhibits the cysteinyl leukotriene CysLT1
receptor. It appears to be useful for the preschool age children,
when there is coexisting allergic rhinitis (Van Adelsberg et al.,
2003), and may also reduce the symptoms, when used as a
short course in intermittent asthma. It has a very narrow spec-
trum of action in comparison to the broad anti-inﬂammatory
action of the commonly used inhaled corticosteroids. It blocks
the action of cysteinyl leukotrienes, which catalyze the inﬂam-
matory cascade from eosinophils, mast cells and alveolar
macrophages (Bisgaard et al., 2005). This reduces the maincharacteristics of asthma, such as airﬂow obstruction, mucus
hypersecretion, mucosal oedema and desquamation, broncho-
constriction, bronchial hyperresponsiveness and eosinophil
accumulation (Smith, 2007). Many drugs are used in the treat-
ment of asthma in children, but in the present study, the objec-
tive was to ﬁnd out a suitable drug which can also reduce the
reactive oxygen species (ROS) production in asthmatic chil-
dren. This is because the ROS play an important role in the
pathogenesis of asthma and oxidative stress contributes to
the initiation and worsening of inﬂammatory respiratory disor-
ders, which include asthma. According to an earlier study,
antioxidant drugs may have a role in reducing or preventing
damage in asthmatic patients (Al-Zamil et al., 2005).
The free radicals and reactive oxygen molecules are gener-
ated by activated neutrophils, monocytes and other cells dur-
ing inﬂammatory processes. In acute inﬂammation, activated
polymorphonuclear leukocytes release lysosomal hydrolytic
enzymes, lipid mediators, and reactive oxygen species that
may damage the surrounding viable tissues (Noiri et al.,
2000). Tugtepe et al. (2007) demonstrated that montelukast
attenuated neutrophil recruitment and promoted the resolu-
tion of inﬂammation by antagonizing the effects of leukotri-
enes, which are potent stimuli for leukocyte inﬁltration. It
has been shown that montelukast acts through the inhibition
of neutrophils in several organs targeted by various inﬂamma-
tory challenges (Sener et al., 2006). The results of the present
study suggest inhibitory effect of the montelukast on reactive
oxygen species (ROS) production in the whole blood (WB)
and isolated PMNs, when stimulated with phorbol myristate
acetate (PMA) and opsonised zymosan (OPZ) in asthmatic
children.
Biber et al. (2009) reported that montelukast has beneﬁcial
effects against the traumatic brain injury induced oxidative
stress in Sprague Dawley rats, suggesting that montelukast,
not only decreases the reactive oxygen species in respiratory
system, but it is also effective against the traumatic brain in-
jury induced oxidative stress.
Anderson et al. (2009) demonstrated the effects of mont-
elukast on the generation of ROS, using the lucigenin and
luminal enhanced CL procedures. They showed that, treat-
ment of the cells with montelukast resulted in a dose-related
inhibition of the generation of ROS, which was evident in both
procedures and which achieved statistical signiﬁcance at the
concentrations of 0.5 lmol/L (lucigenin, P< 0.001) or
1 lmol/L1 (luminol, P< 0.01). Moreover, they found a max-
imal inhibition at 2 lmol/L1 montelukast, resulting in 70%
and 60% inhibition of the generation of ROS with lucigenin
and luminal enhanced CL procedures, respectively.
In the present study, signiﬁcant inhibition of ROS produc-
tion was observed at the lowest concentration of the drug used
without incubation. In this study, montelukast was associated
with more inhibition of PMA-stimulated ROS production in
the whole blood compared with that induced by OPZ as shown
in Table 1. Montelukast was also associated with inhibition of
OPZ-stimulated ROS production in isolated PMNs with that
induced by PMA. This ﬁnding agrees with the earlier reports
which concluded that, depending on the receptor or combina-
tion of receptors, activated different signal transduction path-
ways might be involved in respiratory burst (Della Bianca
et al., 1986). In addition, Raulf and Konig (1988) found that
stimulation of human PMNs with OPZ resulted in time and
dose dependent release of LTB4 and LTC4. On the other
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increase 5-1ipoxygenase kinase activity by translocation of
5-1ipoxygenase to the nucleus and by increasing its capacity for
phosphorylation. Therefore, signal transduction pathways in-
volved in the stimulation of PMA receptors will result in high
5-1ipoxygenase activity (Nagarajan et al., 2000). In the present
study, free radical productions were signiﬁcantly decreased in
the whole blood, when stimulated with PMA (p< 0.04), OPZ
(p< 0.05), and in isolated PMNs when stimulated with OPZ
(p< 0.05) after post medication treatment of montelukast in
asthmatic children. However, no statistically signiﬁcant inhibi-
tion of free radical productions was observed in isolated PMNS
when stimulated with PMA, after post medication treatment of
montelukast in asthmatic children. This difference could be due
to the increase in complement receptor type 3, which is involved
in clearing OPZ on PMNs in asthmatic patients. Based on the
ﬁndings of the present study, we speculate that the activation of
PMNs in asthmatic children results in increased generation of
LTs, which in turn, acts on PMN cys LT1R to stimulate the re-
lease ofROS.The results of this study also suggest thatmonteluk-
ast interferes with this autocrine activation of PMNs by blocking
the cys LT receptors, thereby inhibiting ROS production.
The results of this study suggest that LT receptor antago-
nists represent a novel therapeutic approach with dual beneﬁ-
cial effects, as an antioxidant and an anti-inﬂammatory drug in
the management of pediatric asthma. Furthermore, our ﬁnd-
ings might explain the mechanism of action of cys LTs in pro-
ducing tissue inﬂammation, suggesting that LT receptor
antagonists in addition to their use as anti-inﬂammatory drugs
may also be useful as antioxidants.
The present study had some limitations, including the small
sample size of participating asthmatic children, and the gender
disproportion in the study subjects (38 males vs 10 males). The
severity of asthma was not considered in this study. It is pos-
sible that patients with different severity of asthma react differ-
ently to montelukast. Furthermore, this was an in vitro study,
hence it is suggested that studies with larger sample size are
needed for further in depth evaluation of the role of monteluk-
ast in asthmatic children.
5. Conclusions
Reactive oxygen species (ROSs) play an important role in the
pathogenesis of asthma, and oxidative stress contributes to the
initiation and worsening of inﬂammatory respiratory disorders.
Montelukast was found to decrease the reactive oxygen species
production, both in thewhole blood aswell as the isolatedPMNs,
when stimulated with PMA and OPZ in asthmatic children. It is
therefore suggested that montelukast has an additional role for
the inhibition of ROS production in asthmatic children.
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